Abcam reveals new cell engineering facility in Bay Area

Press release

Cambridge, UK, 08 December 2020 : Today Abcam (AIM:ABC; NASDAQ:ABCM), a global innovator in life science reagents and tools, announced the opening of a new 16,000 sq ft purpose-fitted facility in Fremont, CA, which will serve as a major new site for its specialist cell engineering team. This state-of-the-art facility will enable delivery of engineered cell lines to power expansion of the ready-to-use portfolio and facilitate delivery of customization to meet the demanding needs of research, diagnostic and therapeutic development.

The move follows Abcam’s acquisition of the team and its highly adaptable CRISPR-Cas9-based gene editing platform from Applied Stem Cell earlier this year. The new facility has received significant investment from the business and features an extensive suite of tissue culture labs and is a pivotal part of Abcam’s ambitious growth plans to expand and cement its position in the edited cell line market.

State-of-the-art site will enable rapid delivery of engineered cell lines
Powering ready-to-use edited cell-line portfolio expansion
Enable comprehensive customization for research, diagnostic and therapeutic development

“We are excited to be part of the active and growing biotech community in Fremont with our newest, customized facility. Our cell engineering team are highly experienced and a long-established leader in the edited cell lines market. This facility will enable them to further expand and increase the provision of a comprehensive cell engineering service for a variety of different life sciences applications, at both speed and scale.”

Jac Price
SVP Manufacturing and Supply Chain at Abcam

This enhanced capability builds upon Abcam’s previous acquisition of an extensive range of knockout cell lines from Edigene last year. Ready-made KO cell lines play a significant role in the study and understanding of biological pathways and disease models. Abcam’s gene-edited cell line portfolio and engineering capability is also supporting the company’s award-winning knockout validation initiative, an integral part of the organization’s ongoing efforts to raise reagent quality standards across the industry.

Media contacts

External Communications
external.comms[a]abcam.com

Press release

State-of-the-art site will enable rapid delivery of engineered cell lines

Powering ready-to-use edited cell-line portfolio expansion

Enable comprehensive customization for research, diagnostic and therapeutic development

Media contacts

VIEW PRODUCTS

Statements